Advisory - Ventolin Diskus: One lot recalled as inhalers may not deliver the intended dose
OTTAWA, Feb. 16, 2018 /CNW/ -
Issue Health Canada is advising Canadians that GlaxoSmithKline Inc. is voluntarily recalling one lot of Ventolin Diskus inhalers (lot 786G) because the products may not deliver the intended dose. Individuals who do not receive the intended dose may not be aware that the dose was not delivered.
Ventolin Diskus is a prescription drug used in adults and children 4 years or older to relieve and prevent bronchospasm due to asthma, chronic bronchitis and other chronic lung disorders. Bronchospasm is a sudden worsening of shortness of breath and wheezing. Ventolin Diskus is also used to prevent exercise-induced bronchospasm.
If individuals do not receive the therapeutic dose as expected, their symptoms (cough, wheeze, breathlessness or tight chest) may get worse over time and they can suffer serious health consequences, including a potentially life-threatening asthma attack.
Who is affected
Consumers who use the affected product
Affected product
Ventolin Diskus (200 mcg salbutamol per blister (60 Dose) (DIN 02243115) Lot 786G, Expiry 05 2019
What consumers should do
If you have an inhaler from the affected lot, return it to the pharmacy for a replacement.
If you have questions or concerns about the recall, contact GlaxoSmithKline Inc. (GSK) via Stericycle (which is managing the recall on GSK's behalf) by calling, toll-free, 1-888-714-5077.
Individuals who are experiencing continued symptoms after using their Ventolin Diskus should seek medical attention as soon as possible.
Report adverse events to health products to Health Canada by calling toll-free at 1?866?234?2345, or by reporting online, by mail or by fax.
Report complaints about health products to Health Canada by calling toll-free at 1?800?267?9675, or complete an online complaint form.
What Health Canada is doing Health Canada will monitor the company's recall. Should Health Canada become aware of additional safety information, it will take appropriate action and inform Canadians as necessary.
Background GlaxoSmithKline Inc. has advised Health Canada that it is conducting the recall after identifying a manufacturing issue with the affected lot that may result in a small number of devices not delivering the full number of doses.
Stay connected with Health Canada and receive the latest advisories and product recalls.
Dental Care Acworth is thrilled to utilize this remarkable innovation and offer patients unbiased, objective and standardized dental care that they know they can trust. The AI solutions Pearl delivers can assist dental...
Tolland Hill Family Dental is thrilled to announce the addition of Dr. Conway Ma to its esteemed team of dental professionals. Tolland Hill Family Dental offers a wide range of services, catering to patients of all ages. From a child's first dental...
Amgen today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab, a fully human monoclonal antibody and targeted inhibitor of the insulin-like growth factor-1...
Ractigen Therapeutics, a leader in the development of small activating RNA (saRNA) therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application for RAG-01, a...
Alera Health, a leader in population health management integrating behavioral healthcare, is proud to announce its recognition as one of the Great Employers to Work for in North Carolina by Best Companies Group.
The 2024 Great Employers to Work for...